Trends in Transcatheter Aortic Valve Replacement Outcomes
In this observational cohort study performing a national analysis of outcomes after TAVR, it was found that risk-adjusted 30-day mortality increased modestly from January 2019 to March 2022. However, no site-level, patient-related, or process-related factors were identified that could explain these findings. Although the absolute increase in risk-adjusted mortality during the study period was relatively small, these findings warrant continued surveillance.
Authors
- Vinod H. Thourani (ORCID: https://orcid.org/0000-0002-9309-2623)
- Wayne Batchelor (ORCID: https://orcid.org/0000-0002-3016-1150)
- Michael J. Mack (ORCID: https://orcid.org/0000-0002-3148-9158)
- Suzanne V. Arnold (ORCID: https://orcid.org/0000-0003-3367-0302)
- Andrzej S. Kosinski (ORCID: https://orcid.org/0000-0003-4151-5185)
- Pratik Manandhar (ORCID: https://orcid.org/0000-0002-8294-7147)
- David J. Cohen (ORCID: https://orcid.org/0000-0003-1227-3252)
- Sreekanth Vemulapalli (ORCID: https://orcid.org/0000-0003-1599-2957)
Institutions
- Valve (United States) (US)
- Duke University (US)
- St. Francis Hospital (US)
- Saint Luke's Hospital (US)
- Cardiovascular Research Foundation (US)
- Alaska Heart and Vascular Institute (US)
- Baylor Scott & White Health (US)
- University of Missouri–Kansas City (US)
Publication Details
- Journal
- JAMA Cardiology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1001/jamacardio.2024.3453
- Citations
- 24
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 9.65